Got to love that SONUS reverse takeover. My OGXI shares did not do so well in that takeover, but I bought alot of OGXI at $2 in summer 2008.
I don't know if OGXI will be bought by TEVA if 011 approved. Maybe I overstated it. TEVA may want to buy OGXI because of the rich royalty payments to OXGI. However, why would OGXI sell 427 to anyone. It could be its own little DNDN with 427.
I agree that biotechs do their own research best, but if TEVA is as novel and smart in their approach as people say, then TEVA could buy OGXI and let it have its own division with autonomy to develop the products.
Oh well, this sort of debate in two years would be a very good predicament to be in.
Open label doesn't mean open label to sponsor. It might be open label only to patients and doctors. I don't know whether this is the case, just want to point out this possibility. PARD's pico phase III in SCLC was open label trial, but PARD was blinded until predefined events occured.
If the survival curves diverge enough, there's always a chance the FDA will stop the trial early and grant approval as it did in the case of ONXX's Nexavar. Unusual, but it happens. On the other hand if there's evidence the OGX-011 group is doing worse than the controls, or if something that I think is called a "futility analysis" shows the trial can't succeed, the FDA could end the trial early for those reasons. That scenario is unlikely given the P2 results, but it does make planning a little tricky for those of us who plan to sell or hedge part of our positions before the results are announced.